Adagene Inc. (ADAG) Appoints Cuong Do to its Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
- Qualcomm shares fall on Intel warning and legal concerns
- Marvell Technology shares drop on Lumentum deal concerns
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Oracle shares drop on AI spending concerns and Microsoft criticism
- SpaceX stock drops on launch setback and sector selloff
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
- After-Hours Movers: CLS, AVGO, CDNS, AMKR, WHR
- After-Hours Movers: WDC, BE, DECK, FIX, RNG
Adagene Appoints Cuong Do to Board of Directors and Audit Committee
November 21, 2022 4:05 PM ESTSAN DIEGO and SUZHOU, China, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Adagene Inc. (Adagene) (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, today announced the appointment of Cuong Do, MBA, to Adagenes board of directors (the Board) as an independent director. He will also serve as an audit committee member.
Mr. Do is President and CEO of BioVie Inc., a clinical-stage company developing innovative therapies for Alzheimers Disease, Parkinsons disease and refractory Ascites. Prior to BioVie, Mr. Do was President of Samsungs Global Strategy Group where he... More



